The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like semaglutide (the active ingredient in Ozempic and Wegovy). Media coverage of ...

The MarketWatch News Department was not involved in the creation of this content. -- Average weight loss of 17% if all patients stayed on treatment* with Wegovy(R) (semaglutide) tablets 25 mg (14% ...

Rybelsus ® (semaglutide) tablets 7 mg or 14 mg, the only FDA-approved oral GLP-1 medicine available, now indicated to reduce the risk of major adverse cardiovascular events (MACE) such as CV death, ...